A Crossover Pilot Study of the Effect of Amiloride on Proteinuria

Status unconfirmed · Phase 4

Conditions studied: Proteinuria

In brief

This cross-over study is designed to test the hypothesis that amiloride will reduce urinary protein excretion and protect the kidney from rapid progression in proteinuric kidney disease.

Key facts

Study ID

NCT02522650

Run by

Georgetown University

People needed

30

Starts

2013-07-01

Expected to finish

2021-10-01

Last updated by the study team

2020-02-07

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient with any type of proteinuric kidney diseases
• Aged 18-75
• Proteinuria ≥1g/day
• estimated glomerular filtration rate (eGFR) ≥ 30ml/min/1.73m2

You may not qualify if…

• Clinical evidences of lupus nephritis, or HIV associated nephropathy
• eGFR <30ml/min/1.73m2
• Requirement for treatment with mineralocorticoid receptor antagonists (spironolactone, eplerenone)
• Status post kidney transplant
• Received glucocorticoid steroids within six months
• Serum K >4.8 mmol/L
• Total carbon dioxide <17 mmol/L
• Hemoglobin <10 g/dl
• Contraindicated or allergic to loop diuretics or potassium sparing diuretics
• Abnormal liver function tests

Where it is running

• Georgetown University — Washington D.C., District of Columbia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.